- Home
- ANTX vs TPST Comparison
ANTX vs TPST Comparison
Compare ANTX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- TPST
- Stock Information
- Founded
- ANTX 2017
- TPST 2011
- Country
- ANTX United States
- TPST United States
- Employees
- ANTX N/A
- TPST N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- TPST Health Care
- Exchange
- ANTX Nasdaq
- TPST Nasdaq
- Market Cap
- ANTX 33.2M
- TPST 33.0M
- IPO Year
- ANTX 2022
- TPST N/A
- Fundamental
- Price
- ANTX $1.10
- TPST $6.66
- Analyst Decision
- ANTX Buy
- TPST Hold
- Analyst Count
- ANTX 2
- TPST 3
- Target Price
- ANTX $2.00
- TPST $30.00
- AVG Volume (30 Days)
- ANTX 95.4K
- TPST 72.4K
- Earning Date
- ANTX 08-12-2025
- TPST 08-07-2025
- Dividend Yield
- ANTX N/A
- TPST N/A
- EPS Growth
- ANTX N/A
- TPST N/A
- EPS
- ANTX N/A
- TPST N/A
- Revenue
- ANTX N/A
- TPST N/A
- Revenue This Year
- ANTX N/A
- TPST N/A
- Revenue Next Year
- ANTX N/A
- TPST N/A
- P/E Ratio
- ANTX N/A
- TPST N/A
- Revenue Growth
- ANTX N/A
- TPST N/A
- 52 Week Low
- ANTX $0.87
- TPST $5.35
- 52 Week High
- ANTX $3.07
- TPST $29.38
- Technical
- Relative Strength Index (RSI)
- ANTX 48.42
- TPST 42.36
- Support Level
- ANTX $1.05
- TPST $6.57
- Resistance Level
- ANTX $1.10
- TPST $7.05
- Average True Range (ATR)
- ANTX 0.04
- TPST 0.26
- MACD
- ANTX 0.00
- TPST -0.06
- Stochastic Oscillator
- ANTX 50.00
- TPST 8.45
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.